TG Therapeutics reports Phase II data for umbralisib in CLL

TG Therapeutics Inc. (NASDAQ:TGTX) said once-daily oral umbralisib (TGR-1202) led to nodal reductions in nearly all patients evaluable for response, including three patients with complete resolution of nodal disease, in a Phase II trial to treat relapsed or refractory chronic lymphocytic leukemia (CLL). One patient who achieved complete resolution of nodal disease also had a bone marrow confirmed complete response. Median progression-free survival (PFS) has not yet been reached at a median follow-up of 9.5 months. The data were presented at the American Society of Clinical Oncology (ASCO) meeting in Chicago.

The open-label, U.S. trial enrolled 47 patients with relapsed or refractory CLL who were intolerant to prior Bruton's tyrosine kinase (Btk) or phosphoinositide 3-kinase (PI3K) delta inhibitors...